Charles Schwab’s NanoViricides NNVC Stock Holding History

Charles Schwab’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-2,940	Closed	-$133K	–	3111
2015 Q1	$133K	Hold	2,940	–	–	﹤0.01%	3006
2014 Q4	$160K	Hold	2,940	–	–	﹤0.01%	3015
2014 Q3	$177K	Hold	2,940	–	–	﹤0.01%	2981
2014 Q2	$247K	Buy	+2,940	New	+$209K	﹤0.01%	2939

Other funds holding NNVC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Charles Schwab's NNVC Position: Q2 2015 in Review

Charles Schwab sold out of NanoViricides (NNVC) in Q2 2015, closing a stake of 2,940 shares — an estimated $133K sold.

Charles Schwab first reported a position in NNVC in Q2 2014 and held it in 4 quarters. The position peaked at $247K in Q2 2014. 48 funds tracked by Wall St. Rank hold NNVC as of Q2 2015.

Charles Schwab reported no remaining NanoViricides position as of Q2 2015 after selling out during the quarter.
Charles Schwab sold 2,940 NanoViricides shares in Q2 2015, an estimated $133K.
Charles Schwab first reported a position in NanoViricides in Q2 2014 and held it in 4 quarters.
Charles Schwab's NanoViricides position peaked at $247K in Q2 2014.
48 funds tracked by Wall St. Rank held NanoViricides as of Q2 2015.

Based on Charles Schwab's 13F filing for Q2 2015, filed 14 Aug 2015.